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Summary Genetic changes underlying the progression of human prostate cancer are incompletely understood. Recently, an experimental
model system that resembles human prostate cancer progression was developed based on the serial passage of an androgen-responsive,
non-tumorigenic LNCaP prostate cancer cell line into athymic castrated mice. Six different sublines, derived after one, two or three rounds of
in vivo passage, sequentially acquired androgen independence and tumorigenicity as well as metastatic capacity. Here, we used comparative
genomic hybridization (CGH) and locus-specific fluorescence in situ hybridization (FISH) analysis to search for genetic changes that may
underlie the phenotypic progression events in this model system. Six genetic aberrations were seen by CGH in the parental LNCaP cell line.
The derivative sublines shared virtually all these changes, indicating a common clonal origin, but also contained 3-7 additional genetic
changes. Gain of the 13q12-q13 chromosomal region as well as losses of 4, 6q24-qter, 20p and 21q were associated with androgen
independence and tumorigenicity with additional changes correlating with metastasis. In conclusion, an accumulation of genetic changes
correlates with tumour progression in this experimental in vivo model of prostate cancer progression. It is possible that the specific
chromosomal aberrations involved in this model system may provide clues to the location of genes involved in human prostate cancer
progression and metastasis.
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The incidence ofprostate cancer has risen continuously during the
past decades, and today this malignancy represents the most
common male cancer type in many developed countries (Wingo et
al, 1995). Development of androgen-independent growth as well
as the onset of metastatic dissemination represent the two critical
in vivo progression steps of human prostate cancer that largely
determine the clinical course of the disease and survival of the
patients. While most prostate cancers initially respond favourably
to endocrine manipulation, this therapy is seldom curative.
Therapy resistance often arises as androgen deprivation is
continued. This clinical disease progression is characterized by
expansion of androgen-independent cell clones (Blackard et al,
1973). Prostate cancer metastasises most often to local lymph
nodes as well as haematogeneously to bone (Gittes, 1991). The
distant metastases are most deleterious, especially if they are not
responsive to endocrine therapy. Bone metastases also result in
significant morbidity because of pain, pathological fractures and
spinal cord compression.
Despite the significant clinical implications of prostate cancer
progression, the genetic basis and molecular mechanisms under-
lying the development of androgen-independent growth and
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metastatic ability have remained poorly understood. This is largely
owing to the fact that clinical specimens from tumour sites other
than the primary tumour are difficult to obtain and to the fact
that suitable experimental model systems resembling human
prostate cancer progression have not been available. Only three
well-characterized human prostate cancer cell lines, LNCaP
(Horoszewicz et al, 1983; Gibas et al, 1984), PC-3 (Kaighn et al,
1979) and DU145 (Stone et al, 1978) are widely available. In order
to develop a model system for studies ofthe progression ofhuman
prostate cancer, several sublines characterized by various degrees
of tumorigenicity and metastatic ability were recently established
from a parental LNCaP prostate cancer cell line by in vivo passage
in nude mice (Thalmann et al, 1994; Wu et al, 1994). The parental
LNCaP cell line is non-tumorigenic and is responsive to andro-
gens. After co-inoculation ofthe parental LNCaP cells and human
bone fibroblasts to athymic mice, an androgen-independent C4
subline was generated. This cell line was also able to grow subcu-
taneously in intact male mice as well as in castrated mice when co-
inoculated with bone fibroblasts. However, the C4 cell line
remained non-metastatic. After another in vivo passage of the C4
subline in castrated mice, a second generation subline (C4-2) was
derived. This cell line had acquired a more pronounced androgen-
independent growth pattern and metastasized spontaneously to
lymph nodes and bone. Finally, a number of third-generation
bone-metastatic sublines (B2-B5) were established by collecting
metastatic lesions of the bone from mice inoculated with C4-2.
Overall, these multiple sublines are unique in that they are clonally
derived from the same parental prostate cancer cell line but differ
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Table 1 Phenotypic characteristics of the parental LNCaP cell line and its derivative sublines
Cell line Generation Androgen PSA Tumorigenic Metastatic
(no. of in vivo responsive production
passages) Male Castrated
male
LNCaP 0 Yes Yes No No No
C4 1 No Yes Yes No No
C4-2 2 No Yes Yes Yes Yes
B2 3 No Yes Yes Yes Yes
B3 3 No Yes Yes Yes Yes
B4 3 No Yes Yes Yes Yes
B5 3 No Yes Yes Yes Yes
Tumorigenicity and metastatic potential are defined by administration of parental LNCaP and its sublines subcutaneously to mice
(Thalmann et al, 1994; Wu et al, 1994).
in their phenotypic properties and malignant potential. Several
features ofthis experimental prostate cancer model resemble the in
vivo progression process of human prostate cancer. This suggests
that this model and the derivative cell lines could be used to study
molecular mechanisms and somatic genetic changes that may also
play a role in human prostate cancer progression.
Classical G-banding analysis disclosed a modal chromosome
number around 85 for all the LNCaP sublines as well as the
parental cell line. However, karyotyping was difficult because of
the complexity of the genetic changes. Each cell line typically
carried 7 or 8 different marker chromosomes that could not be
accurately classified by G-banding (Thalmann et al, 1994; Wu et
al, 1994). Comparative genomic hybridization (CGH) makes it
possible to screen for relative DNA sequence copy number differ-
ences across the genome in a single hybridization (Kallioniemi et
al, 1992, 1994). The technique is particularly suitable for compre-
hensive analysis of genetically highly complex tumours as well as
for mapping minute alterations between two abnormal, but geneti-
cally related tumour specimens. CGH is based on a comparative in
situ hybridization of differentially labelled tumour and normal
DNA to normal metaphase spreads. Changes in the tumour to
normal fluorescence ratio quantitated by a digital imaging system
along all the target chromosomes from pter to qter reveal chromo-
somal regions that were either over- or under-represented in the
tumour DNA. Measurement of DNA sequence copy number
changes are expressed relative to the average copy number
(ploidy) ofthe tumour sample.
Here, we applied CGH to analyses of genetic changes associ-
ated with the stepwise progression of the LNCaP cell line in
athymic mouse. The aim was to define whether specific genetic
aberrations appear in this experimental model when the sublines
acquire androgen independence, tumorigenicity and the ability to
metastasize. Genetic changes seen by CGH were subsequently
verified and further delineated by locus-specific fluorescence in
situ hybridization (FISH).
MATERIALS AND METHODS
Prostate cancer cell lines derived from LNCaP
Human prostate cancer cell line LNCaP was originally developed
from a lymph node metastasis by Horoszewicz et al (1983). It is
the only commonly available androgen-responsive prostate cancer
cell line and has been widely used to study androgen regulation of
prostate cancer. Although LNCaP derives from metastatic lesion,
it does not usually form tumours when inoculated subcutaneously
into nude mice (Gleave et al, 1991). The generation of all the
LNCaP sublines, as well as the characterization of their pheno-
typic properties have been described previously by Thalmann et al
(1994) and Wu et al (1994). Briefly, the parental LNCaP cell line
(obtained from Dr G Miller, University of Colorado, Denver, CO,
USA) was co-inoculated with a non-tumorigenic human bone
fibroblast cell line (MS), derived from an osteosarcoma, into
athymic nude male mice. The host was castrated 8 weeks later and
the tumour was harvested at 12 weeks to establish an in vitro
growing tumorigenic and androgen-independent cell line (C4).
The C4 cell line was then again co-injected with MS cells into a
castrated mouse host to develop a second-generation subline
(C4-2). C4-2 cells became spontaneously tumorigenic and
metastatic when injected alone in castrated hosts. A series ofbone
metastatic cell lines (B2, B3, B4 and B5) were generated from
bone metastases ofmice inoculated with the C4-2 cells. The bone-
metastatic sublines had similar tumorigenic and metastatic poten-
tial to the parental C4-2 cells with the exception that tumours
formed more rapidly and disseminated faster (unpublished obser-
vation). The phenotypic features of LNCaP and each of the
sublines are summarized in Table 1. Interphase and metaphase
slide preparations, as well as DNA isolations from the cell lines,
were done according to routine protocols.
Comparative genomic hybridization (CGH)
CGH was performed as described (Kallioniemi et al, 1994).
Briefly, DNAs from the cell lines were labelled by nick translation
with fluorescein isothiocyanate (FITC)-dUTP and normal refer-
ence male DNA with Texas Red-dUTP (both dUTPs were from
DuPont, Boston, MA, USA). Labelled DNAs (400-800 ng each)
were hybridized to normal lymphocyte metaphase spreads using
10 gg of unlabelled Cot-1 DNA to block hybridization to repeat
sequences in the target chromosomes. After a 2-day hybridization,
the slides were washed and counterstained with 1 ,UM 4,6-diami-
dine-2-phenylindole (DAPI) in a Vectashield antifade solution
(Vector Laboratories, Burlingame, CA, USA).
Images of four or more high-quality metaphases were collected
from each slide for quantitative evaluation using a Xillix CCD
camera (Xillix Technologies, Vancouver, BC, Canada) interfaced
to a Nikon SA epifluorescence microscope (Nikon Corporation,
Tokyo, Japan). Each image acquisition consisted ofthree different
exposures on three different-wavelengths corresponding to
FITC (tumour DNA hybridization), Texas Red (reference DNA
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Table 2 Genetic changes in LNCaP parental and sublines by CGH
Cell line Losses Gains
LNCaP 1p34-p36.2, 2, 6cen-q23, 13q 3q13-qter, 19p
Additional changes in sublinesa
C4 3pter-p22, 4, 6q24-qter, 19q13, 20p, 13q12-q13
21q
C4-2 4, 6q24-qter, 20p, 21q 7q, 13q12-q13
B2 3pter-p22, 3pl3-ql3, 4, 6q24-qter, 13q12-q13, 22q
12q21-q23, 20p, 21q
B3 3pter-p22, 3p14-q13, 4, 6q24-qter, 13q12-q13
12q21-q23, 20p, 21q, X
B4 4,6q24-qter,20p,21q 13q12-q13
B5 4, 6q24-qter, 20p, 21q 13ql2-q13
aMost (67-100%) of the genetic changes found in the parental line were also
present in the sublines. Changes found in all of the sublines, but that were
absent from the parental line, are shown in bold.
hybridization) and DAPI (chromosome counterstain used to clas-
sify chromosomes). The images were further processed using
a Sun LX workstation with custom-made CGH software
(Kallioniemi et al, 1994; Piper et al, 1995) based on the Scilimage
package (TNO, Delft, Netherlands).
Quantitation of DNA sequence copy number changes was
accomplished by analysing the hybridization intensities of differ-
entially labelled tumour and normal DNAs along the length of all
chromosomes from pter to qter. After background subtraction, the
absolute fluorescence intensities were normalized so that the
average green to red fluorescence intensity ratio of all chromo-
some objects in each metaphase was 1.0. CGH results were
displayed as green to red copy number plots along the chromo-
somes and were interpreted according to previously published
guidelines (Kallioniemi et al, 1994). Hybridizations of FITC-
labelled normal male DNA against Texas Red-labelled normal
female DNA were used as a negative control (for all autosomes)
and as a linearity check of the hybridization and image analysis
(data from X chromosome). In a successful hybridization, the
green to red fluorescence intensity ratios stayed at approximately
1.0 along all autosomes, whereas a ratio of0.5 was found for the X
chromosome. These control experiments, included in every batch
of hybridization, formed the basis for the interpretation of ratio
differences in the test cases. Chromosomal regions with a mean
ratio of 0.85 were considered lost, and those with a ratio of 1.15
gained in the tumour. MCF-7 breast cancer cell line was used as a
positive control.
Fluorescence in situ hybridization
The CGH results were validated with interphase and metaphase
FISH using locus-specific P1 probes to 3p2l.2 (RMC03PO39),
3q24-25 (RMC03PO67), 13ql2.1 (RMCl3PO25), 13ql4 (RBI
gene, RMC13P001) as well as a cosmid probe forthe 20p11 region
(RMC20CO39). In addition, pericentromeric repeat probes were
used for chromosome 20 (probe RMC20L116, locus D20Z1) and
for 9q12 (pHuR98/D9Z3). The probes were chosen based on the
CGH findings and targeted regions of clear or suspected genetic
aberrations as well as control regions in which no copy number
changes were found by CGH.
Probes were labelled with either biotin-14-dATP or digoxi-
genin-11-dUTP by nick translation. In a two-colour hybridization,
30 ng of locus-specific probe and 5 ng of centromeric probe
together with 10 ,ug ofunlabelled placental DNA were hybridized
overnight to denatured, proteinase K-treated slides. Afterwashing,
the bound probes were visualized with two layers of avidin-FITC
and one layer of anti-digoxigenin rhodamine, and the specimens
were counterstained with DAPI as explained above for CGH. The
same fluorescence microscope and digital image analysis systems
described above for CGH were also used in the FISH analysis. A
minimum of 50 non-overlapping cells with intact morphology
based on the DAPI counterstaining were scored to determine the
copy number of the probe targets in each cell. In addition, at least
20 metaphase spreads were studied to evaluate the distribution of
the signals among the different tumour chromosomes. Normal
lymphocyte interphase nuclei and metaphase chromosomes were
used as hybridization controls to ascertain that all probes were
specific and had a greater than 95% hybridization efficiency.
RESULTS
The CGH results from all cell lines are summarized in Table 2. The
parental LNCaP cell line showed DNA sequence copy number
changes affecting six different chromosomal regions, whereas the
derivative cell lines had 9-13 genetic aberrations. In all cell lines,
including the parental one, most of the changes were relative
losses of chromosome regions. The parental LNCaP cell line
showed losses of the chromosomal regions lp34-p36, 2,
6cen-q23, 13q and gains of3q13-qter and 19p. Almost all ofthese
changes were also seen in the sublines, thereby proving the
common clonal origin ofall lines.
Aberrations at five different chromosomal regions emerged in
the first generation subline C4 and were systematically retained in
all second- and third-generation cell lines. These changes, the
losses of chromosome 4, 6q24-qter, 20p and 21q as well as the
gain of 13q12-q13, may play a critical role in the selection process
that leads to androgen independence and tumorigenicity in nude
mice. Genetic changes that emerged in the second- and third-
generation cell lines were less pronounced. Altogether, five other
chromosomal regions were altered in these different metastatic
sublines. For example, chromosome 7q was gained in C4-2,
possibly reflecting the selection for metastatic ability, whereas
12q21-q23 region was lost in two of the four bone-metastatic
cell lines.
In FISH experiments with a P1 probe for the 13ql2.1 chromo-
somal region, a median ofseven signals (range 3-24) was found in
the C4 subline. This represents about two fold higher copy number
than that seen in the parental LNCaP (median 3). The baseline
ploidy in the LNCaP cells appeared to be tetraploid or near-
tetraploid based on the presence of four copies of signals by FISH
using centromeric probes for regions unaffected in the CGH
analysis (e.g. D20Z1 and D9Z3). Analysis of metaphase prepara-
tions from all ofthe sublines indicated that the extra material orig-
inating from the 13q12 region was seen as a cluster of FISH
signals attached to the distal q-telomere of a derivative chromo-
some 13. This finding is consistent with an intrachromosomal
amplification process of 13ql2 region in this subline, accompa-
nied by a complex duplication and rearrangement of the original
chromosome 13 seen in the parental LNCaP cell line (Figure 1).
According to CGH, the more distal 13ql4-qter region was lost in
all the sublines as well as in the parental LNCaP cell line. This was
confirmed by FISH with an RBI-specific P1 probe, which showed
a median of two copies in all cell lines.




Figure 1 CGH and FISH analyses of genetic changes affecting chromosome 13 in the parental LNCaP prostate cancer cell line (A, B and D) and in the B2
metastatic subline (E, F and H). Digital images of the CGH experiments with the predominantly red colour at the distal 13q indicating loss of this region in both
cell lines (A and E), and the green colour at 13q12-ql13 in the B2 cell line (E) suggesting amplification of this chromosomal region. Mean green to red
fluorescence intensity ratio profiles (± 1 s.d.) are shown from pter (left) to qter (right) of chromosome 13 obtained by quantitative CGH analysis (B and F).
Horizontal dotted lines represent normalized green to red ratio values of 0.85 and 1.15 (cut-off limits for normal ratio variability). The mean ratio is below the
0.85 cut-off along most of the 13q in the parental cell line (B) indicating loss of this region. In the metastatic B2 subline (F), the ratio profiles indicate gain of the
13q12-q13 region and loss of the distal 13q. Ideograms of chromosome 13 are provided for approximate visual reference of the breakpoints (C and G).
Metaphase FISH analysis of the 13q12.1 region (in green) in the parental LNCaP cell line (D) and in the B2 subline (H) using a P1 probe. Chromosome 13s are
counterstained with DAPI (in blue). Two green signals indicate hybridization of the probe to the 13q12.1 region in the parental LNCaP cell line (D). In addition to
signals at the 13q12.1 region, the B2 subline metaphases (H) contained extra signals at the telomeric part of the chromosome suggesting amplification of this
region and rearrangement of chromosome 13
All except the parental cell line showed loss of 20p by CGH.
This was confirmed by FISH analysis, which revealed a median of
two signals by FISH with the 20p probe and four with the chromo-
some 20 centromere probe, while the parental LNCaP cell line had
four copies with both probes. Similarly, low-level gains affecting
the long arm ofchromosome 3 in the various sublines and parental
line by CGH could all be verified by FISH with a P1 probe to the
3q24-q25 region (median copy number 5) and a reference probe
for 3p2l.2 (median copy number 3).
None of the specific genetic aberrations seen by FISH in the
various sublines could be found by FISH in the parental LNCaP
cell line even when an extensive screening of most ofthe cells in a
microscope slide was performed. Although single-colour FISH
analysis has limited sensitivity in detecting very small cell sub-
populations (<1%), the result indicates that the cell selection
during the in vivo passage has been extensive and has led to clones
that are quite distinct from the cells comprising the parental
LNCaP cell culture.
DISCUSSION
CGH and FISH techniques were used to screen for DNA sequence
copy number changes in the LNCaP parental cell line and six
phenotypically distinct clonally derived sublines to identify
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Figure 2 A schematic summary of DNA sequence copy number changes
that arise in conjunction with phenotypic transformation of the LNCaP cell line
based on CGH and FISH analyses
genetic changes associated with the acquisition of androgen-
independent growth, tumorigenicity and metastatic potential. This
experimental model mimics several of the features of human
prostate cancer progression in vivo. The parental LNCaP cell line
contained aberrations in six chromosomal regions by CGH. All of
these changes have previously been reported by CGH in uncul-
tured primary prostate tumours (Cher et al, 1994; Joos et al, 1995;
Visakorpi et al, 1995a). This indicates that the genetic composition
of the parental LNCaP cell line resembles that of human primary
prostate carcinomas and provides a meaningful starting point for
studies of tumour progression.
The overall number of genetic aberrations almost doubled in all
LNCaP sublines compared with the parental line suggesting that
clonal evolution and an accumulation ofgenetic changes underlies
tumour progression in this model system. A similar increase in the
overall number of genetic changes has also been reported during
the progression of human prostate cancer in vivo (Kunimi et al,
1991; Lundgren et al, 1992; Brewster et al, 1994; Koivisto et al,
1995; Visakorpi et al, 1995a) consistent with the multistep
progression model of human cancer (Fearon and Vogelstein,
1990). All sublines shared most if not all genetic changes seen in
the previous generation. This validates that all cell lines are clon-
ally related to one another, and that any changes arising during the
progression of the tumour and cell lines in mice can be associated
with a specific stage of the tumour progression, as well as distin-
guished from those that are characteristic ofthe parental cell line.
Most of the genetic aberrations arose during the first in vivo
passage, concurrent with the transition ofan androgen-responsive,
non-tumorigenic parental LNCaP cell line to an androgen-
independent and tumorigenic C4 subline. Fewer additional
changes were found in the second- and third-generation cell lines
characterizing the acquisition of metastatic potential (C4-2,
B2-B5) (Figure 2). This suggests either that such changes are
beyond the detection limit of the CGH method or that metastatic
dissemination is primarily determined by epigenetic factors or
changes not affecting gene copy number.
Gain of 13ql2-q13 and loss of4, 6q24-qter, 20p and 21q were
seen in the first-generation C4 subline and were retained in all
subsequent sublines suggesting that these genetic changes may be
the most critical ones for the acquisition of in vivo tumorigenicity
and androgen independence in this model system. Losses at chro-
mosomes 4, 20 and 21 involved whole chromosomes or chromo-
some arms making it difficult to pinpoint involvement of any
specific region or gene. These deleted chromosomal regions are
not known to harbour any major tumour-suppressor genes in
human cancer and they have not been reported to be commonly
involved in human primary prostate cancer by any molecular,
cytogenetic or molecular cytogenetic technique. However,
whether such changes appear in androgen-independent metastatic
human carcinomas has not been investigated. The parental LNCaP
showed loss of 6cen-q23, whereas all of the sublines had lost the
whole long arm of the chromosome 6. We have earlier found loss
of 6q (with minimal region of 6cen-q21) in about one-fifth of the
primary prostate carcinomas by CGH (Visakorpi et al, 1995a).
Loss ofheterozygosity at 6q has also been reported in several other
malignancies, including melanoma, ovarian and breast cancer
(Devilee et al, 1991; Millikin et al, 1991; Foulkes et al, 1993).
However, the putative tumour-suppressor genes at 6q region
remain to be identified.
DNA gains and amplifications are known to be involved in
tumour progression and may represent a mechanism for up-regu-
lating specific genes that confer a critical selective advantage to
the cells. Therefore, we decided to study the 13ql2 amplification
seen by CGH in all the derivative cell lines in more detail by
FISH analysis and specific probes for this chromosomal region.
Additional 13ql2-specific FISH signals were attached close to the
telomere of a rearranged parental chromosome 13 resulting in
doubling of the copy number of this region in the sublines
compared with the parental line. The selection ofthe 13q12 probe
was quite arbitrary in this study. It is possible that if a larger selec-
tion ofprobes were tested, a higher level ofamplification could be
found in the core ofthe amplicon (Tanner et al, 1994). 13ql2-ql4
region contains several candidate target genes that are either
already implicated in cancer or could be envisioned to have a
role in cancer. These include the vascular endothelial growth
factor/vascular permeability factor receptor (FLTI), FMS-related
tyrosine kinase 3 (FLT3), fibroblast growth factor 9 (FGF9), G-
protein coupled receptor 12 (GPR12), the breast cancer suscepti-
bility gene (BRCA2) and general transcription factor IIIA
(GTF3A). As demonstrated by us in other amplicons found by
CGH, exclusion of such gene candidates needs to be performed
with expression and copy number analysis using probes specific
for these genes (Tanner et al, 1994; Visakorpi et al, 1995b).
Overall, the results demonstrate how the genome-wide surveys
by CGH provide a powerful tool fordissecting the clonal evolution
and expansion of a cell line when it confronts a selective pressure,
such as androgen deprivation or interactions with organ-specific
stroma. CGH is particularly useful in the analysis of minor clonal
variations between two complex genomes, such as the parental and
the derivative prostate cancer sublines studied here. Differences in
the genetic changes found in such comparisons may reveal impor-
tant clues to the mechanisms ofthe cancerprogression. The critical
question that should be addressed in future studies is to what
extent the genetic changes found in this mouse model system
parallel those found during human prostate cancer progression.
Although the progression events appear similar, the use of
heterotypic cell lines in a mouse background does introduce a
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number of variables and selection events that may be different
from those involved in human prostate cancer progression and
metastasis. There are two possible strategies for translational
studies on the relevance of these findings for human prostate
cancer progression. First, similar longitudinal follow-up studies of
the cancer progression process by CGH and FISH could be
performed in the clinical setting. Any parallel findings would
allow verification of the resemblance of this model system with
the human disease. Such analyses are technically feasible, if
appropriate specimens from the same patient at different stages of
the disease progression were available. Studies on genetic changes
associated with the progression of human prostate cancer during
androgen deprivation therapy in vivo have recently been initiated
in our laboratory and have already led to the identification of
consistent patterns of genetic changes, such as the amplification
of the androgen receptor gene (Koivisto et al, 1995; Visakorpi et
al, 1995a,b). We have, however, been unable to study metastatic
progression ofhuman prostate cancer in vivo owing to difficulty in
obtaining specimens from the distant metastatic sites. Second, an
alternative strategy for future clinical studies would be to identify
and clone genes involved in the cancer progression process in this
experimental model and test for the involvement of these genes in
human cancer.
In conclusion, we have studied genetic changes by CGH and
FISH in the LNCaP prostate cancer cell line and its six sublines,
whose increasingly aggressive phenotype resembles the pheno-
typic progression events occurring during the in vivo progression
and metastasis of human prostate cancer. Results from this experi-
mental model system demonstrate how the increased accumulation
of genetic damage may underlie tumour progression and how
several specific changes, such as the gain of the 13q12-qI 3
region, may have a critical role in this process. Further studies to
identify genes at these chromosomal sites as well as to test for their
involvement in the progression of human prostate cancer are
warranted.
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